Organogenesis Holdings Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Organogenesis Holdings Stock Summary

Organogenesis Holdings competes with Shuttle Pharmaceuticals, Lifecore Biomedical, Redhill Biopharma, Collegium Pharmaceutical, and Alpha Teknova. Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company was founded in 1985 and is headquartered in Canton, Massachusetts. Organogenesis Holdings operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 950 people.

Organogenesis Holdings Key Financial Ratios

Organogenesis Holdings Key Balance Sheet Accounts

Organogenesis Holdings Key Income Statement Accounts

Organogenesis Holdings Key Cash Accounts

Organogenesis Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Organogenesis Holdings's current stock value. Our valuation model uses many indicators to compare Organogenesis Holdings value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Organogenesis Holdings competition to find correlations between indicators driving Organogenesis Holdings's intrinsic value. More Info.Organogenesis Holdings is rated below average in return on equity category among its peers. It is regarded third in return on asset category among its peers reporting about  10.81  of Return On Asset per Return On Equity. At this time, Organogenesis Holdings' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Organogenesis Holdings' earnings, one of the primary drivers of an investment's value.

Organogenesis Holdings Systematic Risk

Today, most investors in Organogenesis Holdings Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Organogenesis Holdings' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Organogenesis Holdings growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Organogenesis Holdings help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Organogenesis Holdings. We use our internally-developed statistical techniques to arrive at the intrinsic value of Organogenesis Holdings based on widely used predictive technical indicators. In general, we focus on analyzing Organogenesis Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Organogenesis Holdings's daily price indicators and compare them against related drivers.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Organogenesis Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in Organogenesis Stock, please use our How to Invest in Organogenesis Holdings guide.You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Organogenesis Holdings. If investors know Organogenesis will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Organogenesis Holdings listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Organogenesis Holdings is measured differently than its book value, which is the value of Organogenesis that is recorded on the company's balance sheet. Investors also form their own opinion of Organogenesis Holdings' value that differs from its market value or its book value, called intrinsic value, which is Organogenesis Holdings' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Organogenesis Holdings' market value can be influenced by many factors that don't directly affect Organogenesis Holdings' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Organogenesis Holdings' value and its price as these two are different measures arrived at by different means. Investors typically determine if Organogenesis Holdings is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Organogenesis Holdings' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.